- Novo Nordisk launches new insulin device
- Study: Participation in diabetes education associated with greater ability to self-manage
- Bydureon pen gets FDA approval
- Study pinpoints protective genetic mutations for Type 2 diabetes
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
PLAINSBORO, N.J. — The Food and Drug Administration has approved two new insulin pens made by Novo Nordisk, the Danish drug maker said Friday.
Novo Nordisk announced the FDA approval of Novolog FlexTouch (insulin aspart [rDNA origin]) and Levemir FlexTouch (insulin detemir [rDNA origin]).
FlexTouch is a new profiled insulin delivery system that allows patients to administer insulin by pressing a low-dose-force button. In traditional insulin pens, a push button extends when a dose is dialed, which can present challenges for a patient at higher doses, the company said.